These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF. Liu LC; Voors AA; Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Chen Y; Greenberg BH; Ponikowski P; Pang PS; Prescott MF; Hua TA; Severin TM; Metra M Clin Res Cardiol; 2016 Sep; 105(9):727-37. PubMed ID: 27017514 [TBL] [Abstract][Full Text] [Related]
4. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Ponikowski P; Unemori E; Voors AA; Adams KF; Dorobantu MI; Grinfeld LR; Jondeau G; Marmor A; Masip J; Pang PS; Werdan K; Teichman SL; Trapani A; Bush CA; Saini R; Schumacher C; Severin TM; Metra M; Lancet; 2013 Jan; 381(9860):29-39. PubMed ID: 23141816 [TBL] [Abstract][Full Text] [Related]
5. Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study. Teerlink JR; Voors AA; Ponikowski P; Pang PS; Greenberg BH; Filippatos G; Felker GM; Davison BA; Cotter G; Gimpelewicz C; Boer-Martins L; Wernsing M; Hua TA; Severin T; Metra M Eur J Heart Fail; 2017 Jun; 19(6):800-809. PubMed ID: 28452195 [TBL] [Abstract][Full Text] [Related]
6. Serelaxin : a potential new drug for the treatment of acute heart failure. Neverova N; Teerlink JR Expert Opin Investig Drugs; 2014 Jul; 23(7):1017-26. PubMed ID: 24865798 [TBL] [Abstract][Full Text] [Related]
7. Evaluating the Efficacy, Safety, and Tolerability of Serelaxin When Added to Standard Therapy in Asian Patients With Acute Heart Failure: Design and Rationale of RELAX-AHF-ASIA Trial. Sato N; Lam CS; Teerlink JR; Greenberg BH; Tsutsui H; Oh BH; Zhang J; Lefkowitz M; Hua TA; Holbro T; Marshood M; Wang XL; Ge J J Card Fail; 2017 Jan; 23(1):63-71. PubMed ID: 27825893 [TBL] [Abstract][Full Text] [Related]
8. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. Metra M; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Ponikowski P; Unemori E; Voors AA; Adams KF; Dorobantu MI; Grinfeld L; Jondeau G; Marmor A; Masip J; Pang PS; Werdan K; Prescott MF; Edwards C; Teichman SL; Trapani A; Bush CA; Saini R; Schumacher C; Severin T; Teerlink JR; J Am Coll Cardiol; 2013 Jan; 61(2):196-206. PubMed ID: 23273292 [TBL] [Abstract][Full Text] [Related]
9. Serelaxin a novel treatment for acute heart failure. Castrini AI; Carubelli V; Lazzarini V; Bonadei I; Lombardi C; Metra M Expert Rev Clin Pharmacol; 2015; 8(5):549-57. PubMed ID: 26294074 [TBL] [Abstract][Full Text] [Related]
10. Targeted biological therapies reach the heart: the case of serelaxin for heart failure. Kumar VA; Wilson SS; Ayaz SI; Levy PD Drugs Today (Barc); 2015 Oct; 51(10):591-7. PubMed ID: 26583301 [TBL] [Abstract][Full Text] [Related]
11. Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study. Felker GM; Teerlink JR; Butler J; Hernandez AF; Miller AB; Cotter G; Davison BA; Filippatos G; Greenberg BH; Ponikowski P; Voors AA; Hua TA; Severin TM; Unemori E; Metra M J Am Coll Cardiol; 2014 Oct; 64(15):1591-8. PubMed ID: 25301463 [TBL] [Abstract][Full Text] [Related]
12. Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial. Filippatos G; Farmakis D; Metra M; Cotter G; Davison BA; Felker GM; Greenberg BH; Hua TA; Pang PS; Ponikowski P; Qian M; Severin TA; Voors AA; Teerlink JR Clin Res Cardiol; 2017 Jun; 106(6):444-456. PubMed ID: 28150186 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAX-AHF-EU. Maggioni AP; López-Sendón J; Nielsen OW; Hallén J; Aalamian-Mattheis M; Wang Y; Ertl G Eur J Heart Fail; 2019 Mar; 21(3):322-333. PubMed ID: 30604559 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic effects of serelaxin in acute heart failure. Du XJ; Hewitson TD; Nguyen MN; Samuel CS Circ J; 2014; 78(3):542-52. PubMed ID: 24451687 [TBL] [Abstract][Full Text] [Related]
15. Renal impairment and worsening of renal function in acute heart failure: can new therapies help? The potential role of serelaxin. Schmieder RE; Mitrovic V; Hengstenberg C Clin Res Cardiol; 2015 Aug; 104(8):621-31. PubMed ID: 25787721 [TBL] [Abstract][Full Text] [Related]
16. Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Serelaxin in Japanese Patients With Acute Heart Failure. Sato N; Takahashi W; Hirayama A; Ajioka M; Takahashi N; Okishige K; Wang X; Maki A; Maruyama H; Ebinger U; Yamaguchi M; Pang Y; Matsumoto H; Kawana M Circ J; 2015; 79(6):1237-47. PubMed ID: 25912697 [TBL] [Abstract][Full Text] [Related]